Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Canagliflozin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Canagliflozin Anhydrous SCHEMBL19293442 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL157162 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL16075101 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493514 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL873848 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL19493519 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL24037935 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL16421559 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL13695263 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 | |
| Canagliflozin Anhydrous SCHEMBL15888791 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ABCB11ADORA3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376819-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| EP-4376829-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| WO-2023006718-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | claimed |
| WO-2023006745-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | claimed |
| EP-4106744-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN FELINES | Boehringer Ingelheim Vetmedica GmbH (DE) | 2022-12-28 | — | — | EP | claimed |
| EP-3262039-A2 | PROCESS FOR THE PREPARATION OF AMORPHOUS (1S)-1,5-ANHVDRO-1-[3-[[5-(4 FLUOROPHENNYL)-2-THIENYL]METHVL]-4-METHYLPHENYL]-D-GLUCITOL AND ITS POLYMORPHS THEREOF | MSN Laboratories Private Limited (IN) | 2018-01-03 | — | — | EP | claimed |
| WO-2016135747-A2 | PROCESS FOR THE PREPARATION OF AMORPHOUS (1S)-1,5-ANHVDRO-1-[3-[[5-(4 FLUOROPHENNYL)-2-THIENYL]METHVL]-4-METHYLPHENYL]-D-GLUCITOL AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-09-01 | — | — | WO | claimed |
| EP-2981269-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2016-02-10 | — | — | EP | claimed |
| WO-2014161836-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-10-09 | — | — | WO | claimed |
| EP-4376819-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | disclosed |
| EP-4376829-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023006745-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF HYPERTENSION IN NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023006718-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN NON-HUMAN MAMMALS EXCLUDING FELINES, IN PARTICULAR CANINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-02-02 | — | — | WO | disclosed |
| EP-4106744-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF CARDIAC DISEASES IN FELINES | Boehringer Ingelheim Vetmedica GmbH (DE) | 2022-12-28 | — | — | EP | disclosed |
| US-7666845-B2 | Compounds having inhibitory activity against sodium-dependent glucose transporter | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-23 | — | — | US | disclosed |
| US-7666845-B2 | Compounds having inhibitory activity against sodium-dependent glucose transporter | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-23 | — | — | US | disclosed |
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | Tanabe Pharma Corporation (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090029927-A1 | COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT GLUCOSE TRANSPORTER | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029927-A1 | COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT GLUCOSE TRANSPORTER | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-29 | — | — | US | disclosed |
| WO-2008070609-A1 | THIENYL-CONTAINING GLYCOPYRANOSYL DERIVATIVES AS ANTIDIABETICS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233874-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS USEFUL AS INHIBITORS OF SGLT | SLC5A1, SLC5A2, SI | SLC5A2 2/4885SLC5A1 1/4885ABCB11 263/4885 |
| US-20090029927-A1 | COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT GLUCOSE TRANSPORTER | SLC5A1, SLC5A2, SLC2A1 | SLC5A2 2/4885SLC5A1 1/4885ABCB11 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.